CVRx Responds to Letter from Pointillist Family Office

CVRx (NASDAQ: CVRX) issued a statement responding to a public letter sent on August 24, 2026 by Jorey Chernett of Pointillist Family Office to CVRx’s board.

Rhea-AI Summary

CVRx (NASDAQ: CVRX) issued a statement responding to a public letter sent on August 24, 2026 by Jorey Chernett of Pointillist Family Office to CVRx’s board. The company said its board and leadership are committed to acting in the best interests of all shareholders and regularly review a range of options to maximize shareholder value.

According to CVRx, the board values shareholder input and has maintained open dialogue with Mr. Chernett. CVRx agreed that its Barostim system is a highly differentiated, clinically validated therapy and currently the only approved neuromodulation therapy for heart failure. The company also agreed that its current valuation does not fully reflect its business potential and stated confidence in its fundamentals and Barostim growth strategy while managing expenses.

Argus Aug 25 session 13 alerts

+6.98% close to close 2.1x rel. volume Open Argus

Details

News Market Reaction – CVRX

+3.7% Peak in 3 hr 27 min

$90.63M Market Cap

On Aug 25, the day this news came out, CVRX closed 6.98% above the previous close. Argus tracked a peak move of +3.7% during that session. Our momentum scanner recorded 13 alerts for this stock that day. Relative volume reached 2.1x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 25 session.

Key Figures

Publication date: Aug. 25, 2026 Letter date: Aug. 24, 2026

Publication date

Aug. 25, 2026

Article dateline

Letter date

Aug. 24, 2026

Public letter referenced by CVRx

Historical Context

5 past events · Latest: Aug 24

5 events

1. Aug 24

   Coverage policy

   24h Move

   +10.9%

   Devoted Health implemented Medicare Advantage coverage for Barostim therapy.

2. Aug 24

   Shareholder activism

   24h Move

   +10.9%

   Shareholder urged the board to prioritize a strategic sale process.

3. Aug 11

   Leadership transition

   24h Move

   +9.9%

   Chief Revenue Officer departed as the company revised its commercial outlook.

4. Aug 06

   Quarterly earnings

   24h Move

   -59.8%

   Quarterly results included a net loss and reduced commercial outlook concerns.

5. Jul 28

   Investor conference

   24h Move

   +1.4%

   Management scheduled a presentation at Canaccord Genuity's growth conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuromodulation, fiduciary duties

2 terms

neuromodulation medical

"only approved neuromodulation therapy for heart failure"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

fiduciary duties regulatory

"consistent with its fiduciary duties to all shareholders"

Fiduciary duties are the legal and ethical responsibilities that company directors, officers, or financial advisors have to put shareholders’ interests ahead of their own, acting with honesty, care, and loyalty. Think of it like a guardian managing someone’s money: choices must prioritize the owner’s benefit, avoid conflicts, and be made with prudent judgment; investors rely on these duties to ensure decisions aren’t self‑serving and to provide grounds for legal action if abused.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement in response to the public letter to CVRx’s Board of Directors from Jorey Chernett at Pointillist Family Office, dated August 24, 2026:

The Board of Directors and leadership team are committed to acting in the best interests of all CVRx shareholders and regularly evaluate a full range of options to maximize value for all shareholders. The Board values all shareholder input and appreciates the open dialogue the Company has maintained with Mr. Chernett.

The Company agrees with Mr. Chernett that Barostim is a highly differentiated, validated therapy protected by a deep moat of clinical evidence, and it remains the only approved neuromodulation therapy for heart failure. The Company also shares Mr. Chernett’s view that CVRx’s current valuation does not fully capture the potential of the underlying business. The Board is confident in the fundamentals of the business and the Company’s strategies to drive Barostim growth while at the same time managing expenses.

The Board is open to constructive engagement with all of its shareholders and will continue to pursue the best course of action consistent with its fiduciary duties to all shareholders.   

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. 

Investor Contact:
Mark Klausner
ICR Healthcare
443-213-0501
ir@cvrx.com 

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CVRx (NASDAQ: CVRX) say in response to the Pointillist Family Office letter on August 25, 2026?

CVRx said its board is committed to acting in the best interests of all shareholders and regularly evaluates options to maximize value. According to CVRx, the board values shareholder input, maintains open dialogue with Jorey Chernett, and remains open to constructive engagement with all shareholders.

How does CVRx describe its Barostim therapy for heart failure in the August 25, 2026 statement?

CVRx described Barostim as a highly differentiated, validated therapy protected by a deep moat of clinical evidence. According to CVRx, Barostim remains the only approved neuromodulation therapy for heart failure, and the company is focused on strategies to drive Barostim growth while managing expenses.

What is CVRx’s view of its current valuation as mentioned in the August 25, 2026 release (ticker CVRX)?

CVRx stated it shares Jorey Chernett’s view that its current valuation does not fully capture the potential of its underlying business. According to CVRx, the board remains confident in the company’s fundamentals and its strategies to grow Barostim while controlling expenses.

How is the CVRx board approaching shareholder value and fiduciary duties in its August 2026 response?

CVRx said its board regularly evaluates a full range of options to maximize value for all shareholders. According to CVRx, the board is open to constructive engagement and will pursue the best course of action consistent with its fiduciary duties to all shareholders.

Does the CVRx (CVRX) statement mention ongoing engagement with Pointillist Family Office and other shareholders?

Yes, CVRx noted it appreciates the open dialogue maintained with Jorey Chernett of Pointillist Family Office. According to CVRx, the board values all shareholder input and is open to constructive engagement with all of its shareholders on maximizing long-term value.